Literature DB >> 27200752

Budget Impact Analysis Of Biosimilar Infliximab For The Treatment Of Crohn's Disease In Six Central Eastern European Countries.

V Brodszky1, L Gulacsi1, O Balogh1, P Baji1, F Rencz1, M Péntek1.   

Abstract

Entities:  

Year:  2014        PMID： 27200752     DOI： 10.1016/j.jval.2014.08.805

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  5 in total

1.  Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.

Authors:  Soo Kyung Cho; Sun Young Jung; Hyoungyoung Kim; Yeo Jin Song; Kyungeun Lee; Yoon Kyoung Sung
Journal:  J Korean Med Sci       Date:  2021-05-24       Impact factor: 2.153

Review 2.  Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.

Authors:  Ira Jacobs; Danielle Petersel; Leah Isakov; Sadiq Lula; K Lea Sewell
Journal:  BioDrugs       Date:  2016-12       Impact factor: 5.807

Review 3.  Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence.

Authors:  Ira Jacobs; Danielle Petersel; Lesley G Shane; Chee-Keng Ng; Carol Kirchhoff; Gregory Finch; Sadiq Lula
Journal:  BioDrugs       Date:  2016-12       Impact factor: 5.807

4.  Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.

Authors:  Paweł Kawalec; Ewa Stawowczyk; Tomas Tesar; Jana Skoupa; Adina Turcu-Stiolica; Maria Dimitrova; Guenka I Petrova; Zinta Rugaja; Agnes Männik; Andras Harsanyi; Pero Draganic
Journal:  Front Pharmacol       Date:  2017-06-08       Impact factor: 5.810

Review 5.  Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.

Authors:  Steven Simoens; Ira Jacobs; Robert Popovian; Leah Isakov; Lesley G Shane
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.